FRAS1 and hepatocellular carcinoma: DST (90.9%), SYNE2 (81.8%), ZFHX4 (81.8%), APOB (63.6%), ASPM (63.6%), FRAS1 (63.6%), KDM6A (63.6%), KEAP1 (63.6%), PEG3 (63.6%), PTPRB (63.6%), MAP1B (54.5%), RPS6KA3 (54.5%), and USP9X (54.5%) were frequently mutated in patients with HCC.